Improved T Cell Activation Bioassays for Development of Bispecific Antibodies and Engineered T Cell Immunotherapies
Poster Dec 07, 2017
Pete Stecha, Denise Garvin, Jim Hartnett, Frank Fan, Mei Cong and Zhi-jie Jey Cheng
Immunotherapy aims to boost a patient’s own immune system to fight disease. In recent years, a variety of immunotherapy strategies aimed at inducing, strengthening or engineering T cell responses have emerged as promising approaches for the treatment of cancer and autoimmune disease.
Here we describe a platform of T cell activation bioassays for the development of CD3 bispecific antibodies and engineered T cell immunotherapies.
Specifically, we developed two bioluminescent reporter-based bioassays to measure T cell activation via CD3 (NFAT-RE) or CD3 + CD28 (IL-2 promoter). These
Genome-wide association studies (GWAS) have identified more than 100 genetic loci associated with type 2 diabetes. The majority of these are located in the intergenic or intragenic regions suggesting that the implicated variants may alter chromatin conformation. This, in turn, is likely to influence the expression of nearby or more remotely located genes to alter beta cell function. At present, however, detailed molecular and functional analyses are still lacking for most of these variants. We recently analysed one of these loci and mapped five causal variants in an islet-specific enhancer cluster within the STARD10 gene locus. Here, we aimed to understand how these causal variants influence b-cell function by alteration of the chromatin structure of enhancer clusterREAD MORE
We show that network analysis of co-localized ions from mass spectrometry imaging data provides a detailed chemo-spatial insight into the metabolic heterogeneity of tumors. Furthermore, module preservation analysis between colorectal cancer patients with and without metastatic recurrence suggests hypotheses on the nature of the different local metabolic pathways.READ MORE